Pediatric Transplantation

This observational, retrospective investigation demonstrates temporal associations pointing to a reassuring vaccine safety profile and mild SARS-Cov-2 infectious phenotype in pediatric renal transplant recipients fully vaccinated against COVID-19.

Timely transplantation has the largest impact on survival in pediatric recipients. Improving waitlist mortality requires uniform surgical expertise at many transplant centers to provide technical variant graft options.

The presence of two biliary anastomoses, and post-transplant complications including acute cellular rejection and early biliary leaks were associated with biliary strictures in pediatric liver transplantation recipients.

In this large cohort of pediatric kidney transplant recipients with antibody mediated rejection, nearly one-third of patients experienced graft failure or significant graft dysfunction within 12 months of diagnosis. Poor graft function at time of diagnosis was associated with higher odds of graft failure.

Excellent short- and long-term kidney transplant graft, gut transplant graft, and patient survival can be achieved through meticulous surgical technique and multidisciplinary peri-operative management of pediatric kidney after gut transplant recipients.

This single-center retrospective study aimed to compare the efficacy and safety of basiliximab versus a single 3 mg/kg dose of anti-thymocyte globulin (r-ATG) induction therapy in pediatric kidney transplant recipients. The r-ATG induction therapy was associated with lower incidence of acute rejection and similar safety profile compared to basiliximab.